Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) Net Income towards Common Stockholders (2017 - 2025)

Selectis Health's Net Income towards Common Stockholders history spans 14 years, with the latest figure at $744865.0 for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders rose 146.13% year-over-year to $744865.0; the TTM value through Sep 2025 reached -$818094.0, up 85.15%, while the annual FY2024 figure was -$2.4 million, 38.85% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was $744865.0 at Selectis Health, up from -$315527.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $4.0 million in Q1 2023 and bottomed at -$3.6 million in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$670969.0 (2025), against an average of -$573950.8.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 534.81% in 2021 before it soared 1656.91% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$1.8 million in 2021, then dropped by 22.32% to -$2.2 million in 2022, then plummeted by 65.5% to -$3.6 million in 2023, then skyrocketed by 84.17% to -$576463.0 in 2024, then skyrocketed by 229.21% to $744865.0 in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Net Income towards Common Stockholders are $744865.0 (Q3 2025), -$315527.0 (Q2 2025), and -$670969.0 (Q1 2025).